ARTICLE | Company News
Clarient, Indiana Research and Technology Corp. (IURTC) deal
April 27, 2009 7:00 AM UTC
Clarient received exclusive, worldwide rights to commercialize IURTC's IP covering the forkhead box A1 (FOXA1) biomarker, which predicts the likelihood of recurrence and long-term, disease-free breas...